Select host restriction factors are associated with HIV persistence during antiretroviral therapy

AIDS

Volumn 29, Issue 4, 2015, Pages 411-420

  Abdel Mohsen, Mohamed ^a   Wang, Charlene ^a   Strain, Matthew C ^b   Lada, Steven M ^c   Deng, Xutao ^d   Cockerham, Leslie R ^e   Pilcher, Christopher D ^b   Hecht, Frederick M ^a   Liegler, Teri ^a   Richman, Douglas D ^b   Deeks, Steven G ^c   Pillai, Satish K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

antiretroviral therapy; HIV latency; host restriction factors; intrinsic immunity; p21; PAF1 complex; schlafen 11

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOLOGIC FACTOR; MESSENGER RNA; POL PROTEIN; PROTEIN P21; RNA POLYMERASE II ASSOCIATED FACTOR 1; SCHLAFEN 11; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LATENT VIRUS INFECTION; LONG TERMINAL REPEAT; MAJOR CLINICAL STUDY; NONPARAMETRIC TEST; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; VIRUS EXPRESSION; VIRUS IMMUNITY; VIRUS LATENCY; VIRUS REPLICATION; CELLULAR IMMUNITY; DRUG EFFECTS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; RNA, VIRAL; VIRAL LOAD; VIRUS LATENCY;

EID: 84922400998     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000572     Document Type: Article

References (61)

1. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295
2. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155
3. Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, Mexas AM, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS One 2013; 8:e71879
4. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501
5. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4R T cells. J Infect Dis 2013; 208:50-56
6. Burbelo PD, Bayat A, Rhodes CS, Hoh R, Martin JN, Fromentin R, et al. HIV antibody characterization as a method to quantify reservoir size during curative interventions. J Infect Dis 2014; 209:1613-1617
7. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347
8. Wang C, Abdel-Mohsen M, Strain MC, Lada SM, Yukl S, Cockerham L, et al. Decreased HIV-1 transcription in CCR5 delta-32 heterozygotes on suppressive antiretroviral therapy. J Infect Dis 2014; 210:1838-1843
9. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3:245-252
10. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430
11. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, et al. CD4R T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011; 121:1549-1560
12. Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 2012; 491:125-128
13. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474:658-661
14. Liu L, Oliveira NM, Cheney KM, Pade C, Dreja H, Bergin AM, et al. A whole genome screen for HIV restriction factors. Retrovirology 2011; 8:94
15. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427:848-853
16. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 2008; 4:e1000007
17. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, et al. Human TRIM gene expression in response to interferons. PLoS One 2009; 4:e4894
18. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 2008; 4:e16
19. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-650
20. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004; 14:1392-1396
21. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004; 78: 6073-6076
22. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 2004; 279: 53379-53386
23. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, et al. Single-strand specificity of APOBEC3G accounts for minusstrand deamination of the HIV genome. Nat Struct Mol Biol 2004; 11:435-442
24. Bourara K, Liegler TJ, Grant RM. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog 2007; 3:1477-1485
25. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 2006; 80:10522-10533
26. Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng YH. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 2008; 283:11606-11614
27. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, et al. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 2011; 7: e1002221
28. Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel D, et al. Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol 2014; 88:763-767
29. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, et al. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 2012; 109:3035-3040
30. Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 2013; 10:106
31. de Masson A, Kirilovsky A, Zoorob R, Avettand-Fenoel V, Morin V, Oudin A, et al. Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4R T cells from elite controllers. AIDS 2014; 28:1567-1577
32. De Pasquale M, Kourteva Y, Allos T, DAquila RT. Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4R T lymphocytes of controllers in vivo. PLoS One 2013; 8:e76002
33. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-551
34. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740
35. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452-463
36. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:RESEARCH0034
37. Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M. Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol 2007; 13:210-224
38. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013; 8:e55943
39. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-1561
40. Ries M, Pritschet K, Schmidt B. Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation. Clin Dev Immunol 2012; 2012: 534929
41. Allouch A, David A, Amie SM, Lahouassa H, Chartier L, Margottin-Goguet F, et al. p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci U S A 2013; 110: E3997-E4006
42. Pauls E, Ruiz A, Riveira-Munoz E, Permanyer M, Badia R, Clotet B, et al. p21 regulates the HIV-1 restriction factor SAMHD1. Proc Natl Acad Sci U S A 2014; 111:E1322-1324
43. Elahi S, Niki T, Hirashima M, Horton H. Galectin-9 binding to Tim-3 renDers activated human CD4R T cells less susceptible to HIV-1 infection. Blood 2012; 119:4192-4204
44. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007; 117:473-481
45. Stewart ZA, Leach SD. Pietenpol JA. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol 1999; 19:205-215
46. Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, et al. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 2006; 3:78
47. Debebe Z, Ammosova T, Breuer D, Lovejoy DB, Kalinowski DS, Kumar K, et al. Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets-iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol 2011; 79:185-196
48. Zhou Q, Li T, Price DH. RNA polymerase II elongation control. Annu Rev Biochem 2012; 81:119-143
49. Guendel I, Agbottah ET, Kehn-Hall K, Kashanchi F. Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther 2010; 7:7
50. Wu W, Kehn-Hall K, Pedati C, Zweier L, Castro I, Klase Z, et al. Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J 2008; 5:41
51. Wang D, de la Fuente C, Deng L, Wang L, Zilberman I, Eadie C, et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 2001; 75:7266-7279
52. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012; 13:223-228
53. Ryoo J, Choi J, Oh C, Kim S, Seo M, Kim SY, et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat Med 2014; 20:936-941
54. Huber AD, Michailidis E, Schultz ML, Ong YT, Bloch N, Puray-Chavez MN, et al. SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2014; 58:4915-4919
55. Amie SM, Daly MB, Noble E, Schinazi RF, Bambara RA, Kim B. Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J Biol Chem 2013; 288:20683-20691
56. Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, et al. A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(R) T cells from elite controllers. Cell Host Microbe 2014; 15:717-728
57. Crisucci EM, Arndt KM. The roles of the Paf1 complex and associated histone modifications in regulating gene expression. Genet Res Int 2011; pii:707641
58. Raposo RA, Abdel-Mohsen M, Bilska M, Montefiori DC, Nixon DF, Pillai SK. Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. J Virol 2013; 87:11924-11929
59. Raposo RA, Abdel-Mohsen M, Deng X, Hecht FM, Pilcher CD, Pillai SK, et al. Dynamic regulation of host restriction factor expression over the course of HIV-1 infection in vivo. J Virol 2014; 88:11624-11629
60. Siliciano JD, Siliciano RF. HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 2013; 8:318-325
61. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20:425-429